Clinical Trials Browser

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

Turcot syndrome, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Esophageal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Disease, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neutropenia, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colonic Polyps, Colorectal Neoplasms

Colorectal Neoplasms

Spinocerebellar Degenerations, Colorectal Neoplasms

Colorectal Neoplasms

Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms, Anastomotic Leak

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Clinical Trials

BEST

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study

FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

JS212 Combination Therapies in Metastatic Colorectal Cancer

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

SAMe in Prevention of Oxaliplatin-associated Liver Injury

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

TRIUNITE-07

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

TORCH-OPTIMA

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

ROMANCE - GOIM

COLIBRI-GI

Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

SMARTi-RC01

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

COLOSOTO

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

ONTOP

BETWEEN

HERBIC

ARK

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

APACOL

The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer